NA
EDIT icon

Neuburgh Advisers’s Editas Medicine EDIT Stock Holding History

Neuburgh Advisers’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-748
Closed -$27K – 889
2018
Q2 		$27K Sell
748
-352
-32% -$12.5K ﹤0.01% 865
2018
Q1 		$36K Buy
+1,100
New +$39.2K ﹤0.01% 871

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Neuburgh Advisers's EDIT Position: Q3 2018 in Review

Neuburgh Advisers sold out of Editas Medicine (EDIT) in Q3 2018, closing a stake of 748 shares — an estimated $27K sold.

Neuburgh Advisers first reported a position in EDIT in Q1 2018 and held it in 2 quarters. The position peaked at $36K in Q1 2018. 199 funds tracked by Wall St. Rank hold EDIT as of Q3 2018.

  • Neuburgh Advisers reported no remaining Editas Medicine position as of Q3 2018 after selling out during the quarter.
  • Neuburgh Advisers sold 748 Editas Medicine shares in Q3 2018, an estimated $27K.
  • Neuburgh Advisers first reported a position in Editas Medicine in Q1 2018 and held it in 2 quarters.
  • Neuburgh Advisers's Editas Medicine position peaked at $36K in Q1 2018.
  • 199 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2018.

Based on Neuburgh Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.